Young child with Doctor

Latest press releases

Tuesday, 22 July 2014
MedImmune and Advaxis partner on immuno-oncology combination clinical trial AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
Friday, 18 July 2014
AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre.
Wednesday, 25 June 2014
FDA Advisory Committee votes on accelerated approval for investigational medicine olaparib AstraZeneca today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have the germline BRCA (gBRCA) mutation, and who are in complete or partial response to platinum-based chemotherapy.
Thursday, 12 June 2014
US FDA Advisory Committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (PAMORA) class including MOVANTIK AstraZeneca announced today that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIK™ (naloxegol oxalate), an investigational treatment for opioid-induced constipation (OIC) for patients with chronic non-cancer pain. Following a clarification of the vote, the majority of the Committee suggested continued post-approval data collection for cardiovascular safety.
Thursday, 12 June 2014
AstraZeneca in-licenses Synairgen's SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma AstraZeneca today announced a global licence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.
Wednesday, 11 June 2014
Brodalumab treatment improved clinical signs and symptoms in Phase II psoriatic arthritis study published in the New England Journal of Medicine Phase III Programme Underway to Further Assess Brodalumab as Potential Treatment for People Living with Psoriatic Arthritis
Wednesday, 11 June 2014
AstraZeneca to present new data from its broad portfolio in wide range of patient populations at the American Diabetes Association 74th Scientific Sessions® AstraZeneca today announced that 43 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentation at the 74th Scientific Sessions® of the American Diabetes Association (ADA) in San Francisco, 13-17 June 2014.
Tuesday, 3 June 2014
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014 AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Tuesday, 3 June 2014
AstraZeneca’s novel antibiotic candidate AZD0914 given Fast Track status by US FDA AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment of uncomplicated gonorrhoea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.
Saturday, 31 May 2014
AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu today presented data on a Phase II study conducted by the American National Cancer Institute (NCI), comparing the efficacy and tolerability of olaparib and cediranib in combination to olaparib alone, for the treatment of women with recurrent platinum-sensitive high-grade serous ovarian cancer (abstract LBA5500). This is the first ovarian cancer study to use a combination of investigational medicines that can be taken orally.